Merkiel K, Prokopowicz J, Bielawiec M, Kiersnowska B
Haematologia (Budap). 1977;11(1-2):111-4.
Serum lysozyme activity has been determined in patients suffering from myeloproliferative diseases, chronic myelogenous leukaemia (CML), acute myelogenous leukaemia (AML), chronic lymphatic leukaemia (CLL) and pancytopenia (P). Lysozyme activity was tested in undiluted and tenfold diluted sera. Increased lysozyme activity was found in patients with CML and CLI, whereas there was no change in patients with AML and P. Dilution of sera enhanced lysozyme activity. These data may indicate the presence of inhibitor in the sera tested. The diagnostic significance of the presented findings is discussed.
已对患有骨髓增殖性疾病、慢性粒细胞白血病（CML）、急性粒细胞白血病（AML）、慢性淋巴细胞白血病（CLL）和全血细胞减少症（P）的患者进行了血清溶菌酶活性测定。在未稀释和稀释十倍的血清中测试了溶菌酶活性。发现CML和CLI患者的溶菌酶活性增加，而AML和P患者则无变化。血清稀释增强了溶菌酶活性。这些数据可能表明所测试的血清中存在抑制剂。讨论了所呈现结果的诊断意义。
